Moderate

Central sleep apnoea

ventilatory control · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Central sleep apnoea reflects loss of ventilatory drive rather than upper-airway collapse, causing repetitive apnoeas without respiratory effort. Common causes include heart failure (Cheyne-Stokes respiration), opioids, high altitude and treatment-emergent central apnoea on CPAP.

Red flags

  • Decompensated heart failure
  • Opioid overdose risk / respiratory depression
  • Severe nocturnal hypoxaemia or hypercapnia
  • New focal neurology (central cause)

Assessment

Differential diagnosis

  • Obstructive sleep apnoea
  • Cheyne-Stokes respiration from heart failure
  • Opioid-induced central apnoea
  • Treatment-emergent central apnoea
  • Hypoventilation syndromes
  • Idiopathic central apnoea

Investigations

  • Full polysomnography differentiating central from obstructive events
  • Echocardiogram and cardiac assessment (ejection fraction)
  • Medication review (opioids, methadone)
  • Arterial/venous blood gas to assess CO2 and acid-base
  • Overnight oximetry/capnography
  • Assess for underlying neurological disease where indicated

Management

  • Confirm predominance of central (effortless) events on polysomnography
  • Identify the underlying cause: heart failure, opioids, altitude, stroke or CPAP-emergent
  • Optimise treatment of underlying heart failure (guideline-directed medical therapy)
  • Reduce or rationalise opioids and other respiratory depressants where possible
  • Trial positive-airway-pressure therapy and distinguish persistent from treatment-emergent central events
  • Avoid adaptive servo-ventilation in symptomatic heart failure with reduced ejection fraction (harm signal)
  • Consider adaptive servo-ventilation for non-heart-failure or idiopathic central apnoea
  • Use supplemental oxygen or CO2-stabilising strategies where appropriate
  • Consider phrenic-nerve stimulation in selected patients
  • Follow up with repeat sleep study to confirm control and monitor symptoms

Drugs & doses

Supplemental oxygen titrated to abolish central events in selected cases
Acetazolamide 250-500 mg PO at night (respiratory stimulant, selected cases)
Optimise heart-failure therapy (ACE inhibitor/ARNI, beta-blocker, diuretic, SGLT2 inhibitor)
Reduce opioid dose / rotate agents where clinically possible

Disposition

Sleep and cardiology joint management; device therapy via sleep service; treat the underlying driver.

Complications & pitfalls

  • Worsening heart failure outcomes
  • Daytime sleepiness and reduced quality of life
  • Arrhythmia
  • Nocturnal hypoxaemia

Exam pearls

  • Adaptive servo-ventilation is contraindicated in symptomatic HFrEF (LVEF <=45%) due to increased mortality
  • Cheyne-Stokes respiration is a marker of heart-failure severity — optimise the heart first
  • Treatment-emergent central apnoea on CPAP often resolves over weeks with continued therapy
  • Review opioids before adding device therapy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.